Persistent infection of human erythroblastoid cells by poliovirus.
Human erythroblastoid K562 cells have been recently described as a relatively nonpermissive host for poliovirus replication. During investigations of virus-induced cytopathic effects in this cell line, we discovered that poliovirus easily established persistently infected cultures in K562-Mu cells. In these cultures, most cells remained viable, with overall viability continuously maintained between 67 and 92% over 3 months. Infected K562 cells continued to grow, usually without any major periods of crisis in the culture or large diminutions in cell growth rate. K562-Mu cells produced a slower onset of virus production than observed in HeLa cells, and virus titers in culture supernates rapidly stabilized at levels between 10(5) and 10(6) PFU/ml. In infectious center or limiting dilution assays, only about 10% of K562 cells produced infectious virus after 2 days. However, when assays were extended to 3 to 5 days, most K562 cells in the culture scored as infectious centers, suggesting productive infection of all cells in the culture with delayed kinetics of virus production. Cultures of infected K562 cells could not be cured of virus by prolonged incubation with high-titer neutralizing antibody. Pulse-label SDS-PAGE analysis of infected cultures detected moderate levels of virus protein synthesis which peaked at 9-12 hr postinfection; however, little or no shutoff of host protein synthesis was observed at any time point during infection. Immunoblot analysis with antisera to the p220 subunit of eIF-4F demonstrated extensive but incomplete cleavage of p220 in infected K562 cells at times which correlated with peak viral protein synthesis. Taken together, the results demonstrate a persistent infection in which host cell shutoff does not occur despite significant viral protein synthesis and extensive early degradation of p220.
Lloyd
R E
RE
Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City 73190.
Bovee
M
M
D000327:Adsorption; D000914:Antibodies, Viral; D002455:Cell Division; D002470:Cell Survival; D002478:Cells, Cultured; D003588:Cytopathogenic Effect, Viral; D004900:Erythroblasts / Q000382:microbiology*; D039562:Eukaryotic Initiation Factor-4F; D006801:Humans; D008565:Membrane Proteins; D009500:Neutralization Tests; D010448:Peptide Initiation Factors / Q000378:metabolism; D017955:Poliovirus / Q000254:growth & development*; D011991:Receptors, Virus / Q000378:metabolism; D014764:Viral Proteins / Q000096:biosynthesis; D014779:Virus Replication
D000914:Antibodies, Viral; D039562:Eukaryotic Initiation Factor-4F; D008565:Membrane Proteins; D010448:Peptide Initiation Factors; D011991:Receptors, Virus; D014764:Viral Proteins; C066100:poliovirus receptor